ECSP066894A - Derivados de sulfonamida-tiazolpiridina como activadores de glucocinasa utiles en el tratamiento de diabetes de tipo 2 - Google Patents

Derivados de sulfonamida-tiazolpiridina como activadores de glucocinasa utiles en el tratamiento de diabetes de tipo 2

Info

Publication number
ECSP066894A
ECSP066894A EC2006006894A ECSP066894A ECSP066894A EC SP066894 A ECSP066894 A EC SP066894A EC 2006006894 A EC2006006894 A EC 2006006894A EC SP066894 A ECSP066894 A EC SP066894A EC SP066894 A ECSP066894 A EC SP066894A
Authority
EC
Ecuador
Prior art keywords
treatment
diabetes
type
thiazolpiridine
sulfonamide
Prior art date
Application number
EC2006006894A
Other languages
English (en)
Inventor
Gregory Raymond Bebernitz
Ramesh Chandra Gupta
Vikrant Vijaykumar Jagtap
Appaji Baburao Mandhare
Davinder Tuli
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP066894A publication Critical patent/ECSP066894A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente invención proporciona compuestos de la fórmula (I), los cuales son activadores de la actividad de glucocinasa y, de esta manera, pueden ser empleados como agentes terapéuticos para el tratamiento de condiciones mediadas por glucocinasa. Por consiguiente, los compuestos de la fórmula (I) pueden ser empleados para la prevención y el tratamiento de tolerancia dañada a glucosa, diabetes de Tipo 2 y obesidad.
EC2006006894A 2004-04-02 2006-09-29 Derivados de sulfonamida-tiazolpiridina como activadores de glucocinasa utiles en el tratamiento de diabetes de tipo 2 ECSP066894A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55918404P 2004-04-02 2004-04-02

Publications (1)

Publication Number Publication Date
ECSP066894A true ECSP066894A (es) 2006-11-24

Family

ID=34963913

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006894A ECSP066894A (es) 2004-04-02 2006-09-29 Derivados de sulfonamida-tiazolpiridina como activadores de glucocinasa utiles en el tratamiento de diabetes de tipo 2

Country Status (19)

Country Link
US (1) US7750020B2 (es)
EP (1) EP1735322B1 (es)
JP (1) JP4700684B2 (es)
KR (1) KR100830007B1 (es)
CN (1) CN1960995B (es)
AR (1) AR050913A1 (es)
AT (1) ATE524479T1 (es)
AU (1) AU2005229416B2 (es)
BR (1) BRPI0509573A (es)
CA (1) CA2560689C (es)
EC (1) ECSP066894A (es)
IL (1) IL178151A0 (es)
MA (1) MA28528B1 (es)
NO (1) NO20064929L (es)
PE (1) PE20061353A1 (es)
PT (1) PT1735322E (es)
RU (1) RU2412192C2 (es)
TN (1) TNSN06315A1 (es)
WO (1) WO2005095418A1 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
WO2004050645A1 (en) 2002-10-03 2004-06-17 Novartis Ag Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
EP1737870A1 (en) * 2004-04-02 2007-01-03 Novartis AG Thiazolopyridine derivates, pharmaceutical conditions containing them and methods of treating glucokinase mediated conditions
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
GT200600429A (es) * 2005-09-30 2007-04-30 Compuestos organicos
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos
CA2627813A1 (en) * 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Substituted pyrrolones as allosteric modulators of glucokinase
CA2627910A1 (en) * 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Substituted cycloalkylpyrrolones as allosteric modulators of glucokinase
CA2627892A1 (en) 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Substituted dihydroisoindolones as allosteric modulators of glucokinase
US7531671B2 (en) * 2005-11-01 2009-05-12 Janssen Pharmaceutica N.V. Dihydroisoindolones as allosteric modulators of glucokinase
WO2007110449A1 (en) 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
TW200815353A (en) 2006-04-13 2008-04-01 Euro Celtique Sa Benzenesulfonamide compounds and their use
US8937181B2 (en) 2006-04-13 2015-01-20 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2046755A2 (en) 2006-07-24 2009-04-15 F. Hoffmann-Roche AG Pyrazoles as glucokinase activators
TW200831081A (en) 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
BRPI0808267A2 (pt) * 2007-03-07 2014-07-22 Kyorin Phamaceutical Co., Ltd "composto representado pela formula geral (1) ou um sal farmeceuticamente aceitável do mesmo; método para o tratamento ou prevenção de diabetes ; uso do composto; composição farmacêutica e composto representado pela formula geral (3)".
WO2008119734A2 (en) * 2007-03-29 2008-10-09 Novartis Ag Process for the manufacture of organic compounds
US8399486B2 (en) 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
US8765736B2 (en) 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
CN101827832B (zh) * 2007-10-08 2014-05-07 阿德维纳斯治疗私人有限公司 作为葡糖激酶活化剂的乙酰胺衍生物、其制备方法及医药应用
CN101417987B (zh) * 2007-10-24 2011-07-13 山东轩竹医药科技有限公司 具有磺酰胺甲酰哌嗪结构的dpp-iv抑制剂
TW200942239A (en) 2008-01-18 2009-10-16 Astellas Pharma Inc Phenylacetamide derivatives
US8258134B2 (en) 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
CA2722733C (en) 2008-04-28 2016-02-23 Kyorin Pharmaceutical Co., Ltd. Cyclopentylacrylamide derivative
BRPI0912802A2 (pt) 2008-05-16 2015-10-13 Takeda San Diego Inc ativadores de glicoquinase
EP2344458A1 (en) 2008-09-11 2011-07-20 Pfizer Inc. Heteroaryls amide derivatives and their use as glucokinase activators
EA018894B1 (ru) 2009-03-11 2013-11-29 Пфайзер Инк. N,n-диметил-5-(2-метил-6-((5-метилпиразин-2-ил)карбамоил)бензо-фуран-4-илокси)пиримидин-2-карбоксамид, используемый в качестве активатора глюкокиназы, и содержащая его фармацев-тическая композиция
US8765747B2 (en) 2009-06-12 2014-07-01 Dana-Farber Cancer Institute, Inc. Fused 2-aminothiazole compounds
US8222416B2 (en) 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
EP2519517B1 (en) 2009-12-29 2015-03-25 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
EP3936608A1 (en) 2010-03-31 2022-01-12 The Scripps Research Institute Reprogramming cells
EP2822935B1 (en) 2011-11-17 2019-05-15 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
WO2013173382A1 (en) * 2012-05-15 2013-11-21 Amgen Inc. Benzothiophene sulfonamides and other compounds that interact with glucokinase regulatory protein
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2014063061A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
EP3057956B1 (en) 2013-10-18 2021-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
US20160264551A1 (en) 2013-10-18 2016-09-15 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
WO2015164604A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2016105528A2 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US10550121B2 (en) 2015-03-27 2020-02-04 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
EP4019515A1 (en) 2015-09-09 2022-06-29 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2242469C2 (ru) * 1999-03-29 2004-12-20 Ф.Хоффманн-Ля Рош Аг Активаторы глюкокиназы
US6320050B1 (en) * 1999-03-29 2001-11-20 Hoffmann-La Roche Inc. Heteroaromatic glucokinase activators
US6610846B1 (en) 1999-03-29 2003-08-26 Hoffman-La Roche Inc. Heteroaromatic glucokinase activators
DK1169312T3 (da) 1999-03-29 2005-01-31 Hoffmann La Roche Glucokinaseaktivatorer
US6353111B1 (en) 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
AU7049401A (en) * 2000-05-03 2001-11-12 Hoffmann La Roche Alkynyl phenyl heteroaromatic glucokinase activators
BR0110492A (pt) * 2000-05-03 2003-04-08 Hoffmann La Roche Composto, composição farmacêutica que compreende esse composto, processo para a preparação de composição farmacêutica, utilização do composto e processo para a preparação do composto
DE60106599T2 (de) * 2000-05-08 2006-02-09 F. Hoffmann-La Roche Ag Substituierte phenylacetamide und ihre verwendung als glukokinase aktivatoren
WO2001085707A1 (en) 2000-05-08 2001-11-15 F. Hoffmann-La Roche Ag Para-amine substituted phenylamide glucokinase activators
US6489485B2 (en) * 2000-05-08 2002-12-03 Hoffmann-La Roche Inc. Para-amine substituted phenylamide glucokinase activators
WO2002008209A1 (en) 2000-07-20 2002-01-31 F. Hoffmann-La Roche Ag Alpha-acyl and alpha-heteroatom-substituted benzene acetamide glucokinase activators
US6369232B1 (en) * 2000-08-15 2002-04-09 Hoffmann-La Roche Inc. Tetrazolyl-phenyl acetamide glucokinase activators
US6433188B1 (en) * 2000-12-06 2002-08-13 Wendy Lea Corbett Fused heteroaromatic glucokinase activators
PT1341774E (pt) * 2000-12-06 2006-05-31 Hoffmann La Roche Activadores heteroaromaticos, fundidos de glicocinase
US6482951B2 (en) 2000-12-13 2002-11-19 Hoffmann-La Roche Inc. Isoindolin-1-one glucokinase activators
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
US6911545B2 (en) 2001-12-19 2005-06-28 Hoffman-La Roche Inc. Crystals of glucokinase and methods of growing them
BR0215212A (pt) 2001-12-21 2004-12-07 Novo Nordisk As Ativador de carboxamida ou sulfonamida de glicoquinase, composto, composição farmacêutica, e, uso de um composto
JP4419571B2 (ja) * 2002-03-26 2010-02-24 萬有製薬株式会社 新規アミノベンズアミド誘導体
JP4091600B2 (ja) 2002-04-26 2008-05-28 エフ．ホフマン−ラ ロシュ アーゲー 置換フェニルアセトアミド及びグルコキナーゼ活性化物質としてのその使用
JPWO2003097824A1 (ja) 2002-05-16 2005-09-15 萬有製薬株式会社 グルコキナーゼタンパク質の結晶、及びその結晶を用いたドラッグデザイン方法
KR101116627B1 (ko) 2002-06-27 2012-10-09 노보 노르디스크 에이/에스 치료제로서 아릴 카르보닐 유도체
WO2004050645A1 (en) * 2002-10-03 2004-06-17 Novartis Ag Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
WO2004031179A1 (en) 2002-10-03 2004-04-15 F. Hoffmann-La Roche Ag Indole-3-carboxamides as glucokinase (gk) activators
MY141521A (en) 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
ES2362656T3 (es) 2003-01-06 2011-07-11 Eli Lilly And Company Arilciclopropilacetamidas sustituidas como activadores de glucoquinasa.
WO2004063194A1 (en) 2003-01-06 2004-07-29 Eli Lilly And Company Heteroaryl compounds
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
WO2004072066A1 (en) 2003-02-11 2004-08-26 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
NZ540791A (en) 2003-02-13 2009-09-25 Banyu Pharma Co Ltd Novel 2-pyridinecarboxamide derivatives
MXPA05009059A (es) 2003-02-26 2005-10-19 Banyu Pharma Co Ltd Derivados de heteroarilcarbamoilbenceno.
EP1737870A1 (en) * 2004-04-02 2007-01-03 Novartis AG Thiazolopyridine derivates, pharmaceutical conditions containing them and methods of treating glucokinase mediated conditions
JP2007533722A (ja) 2004-04-21 2007-11-22 プロシディオン・リミテッド トリ（シクロ）置換アミド化合物
MX2007001650A (es) 2004-08-12 2007-07-13 Prosidion Ltd Fenilacetamidas substituidas y su uso como activadores de glucocinasa.
CA2590720A1 (en) 2004-12-03 2006-06-08 Lone Jeppesen Heteroaromatic glucokinase activators
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos

Also Published As

Publication number Publication date
MA28528B1 (fr) 2007-04-03
CN1960995B (zh) 2010-12-08
AU2005229416B2 (en) 2009-03-26
CA2560689A1 (en) 2005-10-13
TNSN06315A1 (en) 2007-12-03
BRPI0509573A (pt) 2007-09-25
US20080103167A1 (en) 2008-05-01
WO2005095418A1 (en) 2005-10-13
PE20061353A1 (es) 2006-12-29
EP1735322A1 (en) 2006-12-27
ATE524479T1 (de) 2011-09-15
AU2005229416A1 (en) 2005-10-13
KR20060131955A (ko) 2006-12-20
JP4700684B2 (ja) 2011-06-15
NO20064929L (no) 2006-12-20
JP2007530632A (ja) 2007-11-01
US7750020B2 (en) 2010-07-06
CN1960995A (zh) 2007-05-09
EP1735322B1 (en) 2011-09-14
CA2560689C (en) 2011-03-01
AR050913A1 (es) 2006-12-06
IL178151A0 (en) 2006-12-31
PT1735322E (pt) 2012-01-12
RU2412192C2 (ru) 2011-02-20
RU2006138433A (ru) 2008-05-10
KR100830007B1 (ko) 2008-05-15

Similar Documents

Publication Publication Date Title
ECSP066894A (es) Derivados de sulfonamida-tiazolpiridina como activadores de glucocinasa utiles en el tratamiento de diabetes de tipo 2
GT200600429A (es) Compuestos organicos
UY28005A1 (es) Indol -3-carboxamidas como activadores de glucoquinasa (gk)
BRPI0509543A (pt) derivados de tiazolopiridina, condições farmacêuticas que contêm os mesmos e métodos para tratar condições mediadas por glucocinase
CR9078A (es) Derivado de bencimidazol ariloxi-sustituidos
CO6270223A2 (es) Derivados de piridin-2-ilamino-1,2,4 tiadiazol como activadores de glucocinasa para el tratamiento de diabetes mellitus
DOP2006000052A (es) Alargar el tiempo hasta la progresión de la enfermedad o la supervivencia de los pacientes de cáncer
ECSP044935A (es) Inhibidores de la dipeptidil peptidasa beta-amino heterocíclica para el tratamiento o la prevención de la diabetes
UY28923A1 (es) Compuestos terapéuticos: piridina como estructura base
UY29258A1 (es) Ácidos hidroxibifenilcarboxílicos y derivados, procedimientos para prepararlos y su uso
NI200700169A (es) Derivados del pirimidinil y piridinil sustituidos como moduladores del metabolismo y el tratamiento de desordenes relacionados con el mismo.
UY30641A1 (es) Derivados de 2-[1h-pirazol-5-il] y de 2-[2h-pirazol-3-il]tieno[3,2-c]piridinas sustituidas, sus sales farmaceuticamente aceptables y aplicaciones
UY28774A1 (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes.
ECSP045474A (es) 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de 5-hidroxitriptamina-6
ATE539748T1 (de) Glucokinaseaktivatoren
ECSP067121A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
ECSP067098A (es) Compuestos y metodos para el tratamiento de dislipidemia
CL2007002492A1 (es) Compuestos derivados de bi-,tri o policiclos no aromaticos, inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo i; proceso de preparacion de estos; composicion famaceutica que los comprende; uso en el tratamiento de enfermedades tales como la obesidad, diabetes y dislipidemia, entre otras.
UY29020A1 (es) Saliciltiazoles sustituidos con difenilamina o derivados de difenilamina, procedimientos para su preparacinn y su uso.-
UY28726A1 (es) N-ciclohexilimidazolinonas sustituidas.procedimientos para su preparación y su uso como medicamentos.
ECSP034811A (es) Derivados heterocicliloxi-, -tioxi - y - aminobenzazole tales como ligandos 5-hidroxitriptamina-6
NI200700032A (es) Derivados arilsulfonilestilbeno para tratamiento de insomnio y afecciones relacionadas
ECSP045156A (es) Derivados de indolilalquilamina como ligandos 5-hidroxitriptamina-6
UY28098A1 (es) Derivados de anilinopirazol útiles en el tratamiento de la diabetes
DK1809270T3 (da) 5,6,7-trihydroxyheptansyre og analoger til behandling af okulære sygdomme og sygdomme associeret med hyperproliferative og angiogeniske reaktioner